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Aim: To assess the impact of faster aspart vs insulin aspart on long-term clinical outcomes and
costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting.
Methods: The QuintilesIMS CORE Diabetes Model was used to project clinical outcomes and costs
over patient lifetimes in a cohort with data on baseline characteristics from the “onset 1” trial. Treat-
ment effects were taken from the 26-week main phase of the onset 1 trial, with costs and utilities
based on literature review. Future costs and clinical benefits were discounted at 3.5% annually.
Results: Projections indicated that faster aspart was associated with improved discounted
quality-adjusted life expectancy (by 0.13 quality-adjusted life-years) vs insulin aspart. Improved
clinical outcomes resulted from fewer diabetes-related complications and a delayed time to
their onset with faster aspart. Faster aspart was found to be associated with reduced costs vs
insulin aspart (cost savings of £1715), resulting from diabetes-related complications avoided
and reduced treatment costs.
Conclusions: Faster aspart was associated with improved clinical outcomes and cost savings vs
insulin aspart for patients with T1DM in the UK setting.
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1 | INTRODUCTION
It has been estimated that there are 370 000 adults and 26 500 chil-
dren living with type 1 diabetes mellitus (T1DM) in the UK.1,2
Patients with T1DM are at a higher risk of chronic complications and
mortality than people without diabetes of the same age.3 In 2010/
2011, the direct costs attributable to T1DM in the UK were approxi-
mately £1 bn.4 In addition, it is estimated that 830 000 sick days are
taken per year as a result of T1DM, leading to indirect costs of
approximately £0.9 bn. Projections suggest that, if no changes are
made to treatment patterns, direct and indirect costs will increase to
£1.8 and £2.4 bn, respectively, by 2035/2036.4
Long-term studies in patients with T1DM, such as the Diabetes
Control and Complications Trial (DCCT) and the follow-up Epidemiol-
ogy of Diabetes Interventions and Complications (EDIC) study,
suggest that improving glycaemic control can reduce the incidence of
diabetes-related complications, lowering the clinical and economic
burden of the disease.5,6 In the UK in 2015, however, only 29.9% of
patients with T1DM were achieving the glycaemic control target of
glycated haemoglobin (HbA1c) < 7.5%.7 This target has recently been
lowered to 6.5% by the National Institute for Health and Care Excel-
lence (NICE), and whilst no data have been published on the propor-
tion of patients achieving the revised target, it is likely to be lower
than for the previous guidance.1
Fast-acting insulin aspart (faster aspart) is conventional insulin
aspart (insulin aspart) in a new formulation for the treatment of dia-
betes requiring insulin. Faster aspart has been developed to have
a faster onset of action which more closely matches physiological
secretion of endogenous insulin.8 When compared with insulin
aspart, faster aspart has a twice faster onset of appearance in
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the bloodstream, a twice higher insulin exposure within the first
30 minutes and a 74% greater glucose-lowering effect in the first
30 minutes after administration.9
“Onset 1” was a 26-week multicentre, multinational, double-blind
trial in patients with T1DM in which faster aspart was compared with
insulin aspart, both in combination with insulin detemir in a basal-
bolus insulin regimen.10 The trial also included a 26-week open-label
faster aspart post-meal dosing arm (also in combination with insulin
detemir). The initial 26-week trial period was followed by an addi-
tional 26-week treatment period to assess long-term safety and effi-
cacy. Compared with insulin aspart, mealtime faster aspart was
associated with a significantly greater reduction in the primary end-
point of the trial, HbA1c at 26 weeks. Faster aspart administered
post-meal did not compromise glycaemic control compared with insu-
lin aspart administered at mealtime. Faster aspart compared with
insulin aspart, both administered at mealtime, was also associated
with statistically significant improvements in 1- and 2-hour postpran-
dial glucose (PPG) increments. No statistically significant differences
in changes in body weight or rates of hypoglycaemic events were
observed, and the safety profiles of faster aspart and insulin aspart
were similar.
Economic evaluation of new healthcare interventions plays a key
role in ensuring efficient allocation of limited healthcare resources
within the National Health Service (NHS), with the aim of maximizing
healthcare gains across the population of the UK. In the UK, faster
aspart and insulin aspart are associated with the same acquisition
cost. The aim of the present study, therefore, was to assess the
impact of basal-bolus insulin therapy with mealtime faster aspart plus
insulin detemir vs mealtime insulin aspart plus insulin detemir on
long-term clinical outcomes and costs in patients with T1DM, from a
healthcare payer perspective in the UK setting.11
2 | MATERIALS AND METHODS
2.1 | Model description
The analysis was performed using the QuintilesIMS CORE Diabetes
Model.12 This model is a validated, non-product-specific diabetes pol-
icy analysis tool and is based on a series of interdependent submo-
dels that simulate the complications of diabetes. The model uses data
from a range of published long-term clinical and epidemiological stud-
ies to make predictions of outcomes, including the Diabetes Control
and Complications Trial (DCCT), the UK Prospective Diabetes Study
(UKPDS), the Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR), the US Renal Disease Study (USRDS) and many others.12
Long-term outcomes projected by the model have been validated
against real-life data in 2004 and more recently in 2014.13,14 Version
9.0 of the QuintilesIMS CORE Diabetes Model was used in the pres-
ent analysis, as this model update includes risk equations specific to
T1DM based on data from the EDIC study, and the Pittsburgh Epide-
miology of Diabetes Complications Study, and includes the option to
use a diminishing disutility for non-severe hypoglycaemic events.15
Outcomes were projected over patient lifetimes (up to 70 years)
to capture all relevant long-term complications and associated costs
and assess their impact on life expectancy and quality-adjusted life
expectancy, consistent with good practice guidance for economic
evaluation of interventions for diabetes.16 Future clinical benefits and
costs were discounted at 3.5% annually, based on health economic
guidance for the UK setting.17
2.2 | Simulated cohort and treatment effects
The baseline cohort characteristics applied in the analysis were based
on all patients included in the onset 1 study.10 The mean (standard
deviation [s.d.]) age was 44.4 (13.9) years, with mean duration of dia-
betes of 19.9 (12.3) years, and mean HbA1c of 7.6 (0.7)%. The pro-
portion of patients using tobacco products was based on the trial
data, but the number of cigarettes smoked per day was assumed to
be the same as the general UK population and was based on country-
specific data, as was alcohol consumption.18,19
Treatment effects applied in the faster aspart and insulin aspart
arms (both in combination with insulin detemir) were taken from the
26-week main phase of the trial, in line with the primary endpoint,
with data from mealtime insulin administration used (Table 1). Mod-
elled data were used to account for any differences in the baseline
cohort characteristics between the treatment arms.10
After application of the treatment effects in the first year of the
analysis, HbA1c was assumed to remain constant over time. There
are currently no published progression equations for HbA1c in
patients with T1DM, and data from long-term studies such as DCCT
and EDIC suggest that HbA1c does not increase as patients age.6
Unlike type 2 diabetes mellitus (T2DM), T1DM is not a progressive
disease and it is unlikely that substantial changes in HbA1c over time
would be observed. Patients were assumed to receive faster aspart
plus insulin detemir or insulin aspart plus insulin detemir for the dura-
tion of their lifetimes, with no treatment switching applied.
TABLE 1 Treatment effects applied in the first year of the analysis
Faster aspart Insulin aspart
Mean (s.d.) Mean (s.d.)
HbA1c, % −0.32 (0.56)* −0.17 (0.56)
Systolic blood pressure, mm Hg −1.47 (11.70) −1.15 (11.70)
Diastolic blood pressure, mm Hg −0.40 (9.40) +0.40 (8.90)
Total cholesterol, mg/dL +0.01 (0.65) +0.02 (0.65)
HDL cholesterol, mg/dL +0.01 (0.25) −0.01 (0.25)
LDL cholesterol, mg/dL −0.01 (0.53) 0.00 (0.53)
Triglycerides, mg/dL +0.01 (0.62) +0.07 (0.62)
Body mass index, kg/m2 +0.23 (0.99) +0.19 (0.99)
Severe hypoglycaemia event
rate (events
per 100 patient years)
25 27
Non-severe hypoglycaemia
event rate
(events per 100 patient years)
5849 5811
Percentage of severe hypoglycaemic
events that were nocturnal (%)
24.0 37.0
Percentage of non-severe
hypoglycaemic events
that were nocturnal (%)
12.0 13.0
Abbreviations: HbA1c, glycated haemoglobin; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein.
*P < .05.
2 RUSSELL-JONES ET AL.
2.3 | Costs and utilities
Costs were accounted from a healthcare payer perspective (NHS) in
2015 pounds sterling (£). Diabetes medication resource use was
based on the onset 1 trial, with modelled doses taken from the 26-
week main phase of the trial. At the end of the trial, patients in the
faster aspart arm received mean daily doses of 30.60 and 30.44 IU
basal and bolus insulin, respectively, compared with 31.24 and
33.06 IU per day in the insulin aspart arm. Costs of medications and
consumables (needles and self-monitoring of blood glucose test strips
and lancets) were taken from the Monthly Index of Medical
Specialities.11
Costs of treating diabetes-related complications were identified
through literature review, with costs inflated to 2015 values using
the Hospital and Community Health Services price index where
necessary.20–30 Over time, patients develop complications that influ-
ence their overall health-related quality of life and therefore utilities,
reflecting the patients quality of life, were applied in the year of the
complication and in subsequent years based on published
sources.12,31–33 Whilst utilities specific to T1DM have been pub-
lished, no full set of utilities for all complications included in the
QuintilesIMS CORE Diabetes Model have been published using a sin-
gle method. There is significant evidence that utility estimates vary
depending on the methods used, therefore, the majority of utilities
were based on patients with T2DM or the general population, with
consistency in the methodology used to elicit the values. Application
of utilities for patients with T2DM in patients with T1DM is a com-
mon approach in cost-effectiveness analyses of interventions for
T1DM.34–37 For disutilities applied after non-severe hypoglycaemic
events, a diminishing disutility approach as described by Lauridsen
et al.38 was used. This approach was chosen as there is evidence that
the marginal impact of non-severe hypoglycaemia on quality of life
falls as the frequency of hypoglycaemic events increases.
2.4 | Sensitivity analyses
Sensitivity analyses were conducted to evaluate the key drivers of
outcomes and to assess the effect of changes in modelling assump-
tions on the projected outcomes. The influence of time horizon on
the outcomes projected by the model was investigated by running
analyses over 10, 20 and 30 years. It should be noted that a time
horizon of 70 years was required for all modelled patients to have
died, and therefore shorter time horizons do not capture all complica-
tions and costs. To examine the effect of discounting on outcomes,
simulations were performed with (symmetric) discount rates of 0%
and 6%. A total of five simulations were run to assess the key drivers
of clinical benefit associated with faster aspart. In the faster aspart
arm, changes in HbA1c, blood pressure, serum lipids, body mass index
and hypoglycaemic events were set to the value in the insulin aspart
arm in turn. A further analysis with only the statistically significant
difference in HbA1c applied in the faster aspart arm, with all other
parameters equal to the insulin aspart arm, was conducted.
To evaluate the impact of alternative assumptions around long-
term parameter progression on projected outcomes, 5 sensitivity ana-
lyses were conducted. In the base case analysis, the difference in
HbA1c between the treatment arms was assumed to persist for the
entire simulation, with sensitivity analyses conducted with the differ-
ence abolished after 1, 5 and 10 years. A further analysis was con-
ducted with the HbA1c difference abolished linearly over 10 years
(ie, the difference between the treatment arms disappeared gradu-
ally). A final analysis was conducted with HbA1c difference between
the treatment arms maintained for the duration of patient lifetimes,
but an increase of 0.045% per year was applied in both arms, based
on data from the DCCT.5 This analysis reflects that patients with
T1DM may develop some characteristics of T2DM due to weight
gain and family history. In contrast to T1DM, T2DM is a progressive
disease, with insulin resistance increasing and β-cell function declining
over time.
The effect of over- or underestimating the direct cost of treating
diabetes-related complications was investigated in 2 scenarios, by
increasing and decreasing costs of complications by 20%. The base
case analysis was conducted using a diminishing disutility approach
for non-severe hypoglycaemic events, and a sensitivity analysis was
conducted using a static disutility approach with disutilities applied
based on T1DM-specific data from Evans et al.32,38 The impact of
hypoglycaemia disutilities was further explored in an analysis with no
disutility applied after severe and non-severe events.
Version 9.0 of the QuintilesIMS Core Diabetes Model incorpo-
rates a number of risk equations to predict cardiovascular mortality
and varying of the risk equations applied can be used to address struc-
tural uncertainty. The base case analysis used risk equations derived
from the EDIC study, with risk equations based on data from the Pitts-
burgh Epidemiology of Diabetes Complications Study applied in a sen-
sitivity analysis.39 In a further sensitivity analysis to examine structural
uncertainty, a combined mortality risk equation was applied.40
Reflecting the primary endpoint of onset 1, the 26-week data
were applied in the base case analysis. The 52-week data, including
the additional 26-week treatment period, were used in a sensitivity
analysis with equivalent assumptions. An analysis was also conducted
with the 26-week data applied in the first year of the analysis, and
then treatment effects were applied to bring parameters to the values
seen at 52 weeks in the second year of the analysis (the QuintilesIMS
CORE Diabetes Model uses an annual cycle, and therefore it was not
possible to apply changes at 6 months). Probabilistic sensitivity analy-
sis was performed using a second-order Monte Carlo approach with
sampling of baseline cohort characteristics, treatment effects, costs
and utilities.
3 | RESULTS
3.1 | Base case analysis
In the base case analysis, long-term projections showed that faster
aspart was associated with improved discounted life expectancy
(by 0.11 years) and discounted quality-adjusted life expectancy
(by 0.13 quality-adjusted life-years [QALYs]) vs insulin aspart in
patients with T1DM (Table 2). Improved clinical outcomes resulted
from a reduced incidence of diabetes-related complications over
patient lifetimes (Figure 1A). In addition to a reduced incidence of
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complications, faster aspart was associated with a delayed time to
onset of complications (Figure 1B), with mean time free of all compli-
cations increased by ~6 months and mean time to onset of myocar-
dial infarction, stroke, end-stage renal disease, severe vision loss and
amputation all delayed by 4 to 6 months.
Evaluation of direct costs suggested that the mean cost per
patient receiving faster aspart was £1715 lower than in the insulin
aspart arm over a patient lifetime (Figure 2A). Faster aspart was
associated with cost savings as a result of avoided diabetes-related
complications, most notably as a result of avoided ulcer and neurop-
athy complications, and avoided ophthalmic complications, where
mean per-patient savings of £516 and £225, respectively, were iden-
tified. Faster aspart was associated with cost savings after 1 year
for the majority of complications, but cost savings as a result of
avoided renal complications were only apparent after 15 years
(Figure 2B). Cost savings as a result of all complications avoided
increased over patient lifetimes, before plateauing 40 years into the
analysis. Faster aspart was also associated with reduced treatment
costs, driven by the lower doses of basal and bolus insulins, with
mean cost savings of £478 per patient. Estimation of long-term clini-
cal outcomes indicated that both life expectancy and quality-
adjusted life expectancy were improved with faster aspart treatment
TABLE 2 Results of the base case analysis
Faster aspart Insulin aspart Difference
Mean (s.d.) Mean (s.d.)
Discounted life expectancy, years 17.38 (0.16) 17.27 (0.19) +0.11
Discounted quality-adjusted life expectancy, QALYs 11.54 (0.12) 11.40 (0.14) +0.13
Discounted direct costs, £ 50 004 (1363) 51 719 (1261) −1715
ICER (life expectancy) Faster aspart dominant
ICER (quality-adjusted life expectancy) Faster aspart dominant
Abbreviation: ICER, incremental cost-effectiveness ratio.
Costs are in 2015 pounds sterling (£).
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compared with insulin aspart, at a cost saving from a healthcare
payer perspective.
3.2 | Sensitivity analyses
Faster aspart was associated with improved clinical outcomes and
reduced costs from a healthcare payer perspective vs insulin aspart in
all sensitivity analyses conducted (Table 3). Variation in the time hori-
zon had the greatest impact on the results. Over shorter time hori-
zons, faster aspart was associated with smaller clinical benefits and
smaller cost savings than in the base case analysis. This was due to
the improvements in physiological markers (predominantly HbA1c)
associated with faster aspart resulting in a reduced risk of diabetes-
related complications over the long term. Changing the discount rates
also highlighted the long-term benefits of improved glycaemic control
with faster aspart, with clinical benefits and cost savings increased
when discount rates of 0% were applied.
Abolishing each of the changes in physiological variables associated
with faster aspart identified that the improvement in HbA1c compared
with insulin aspart was the key driver of improved clinical outcomes and
cost savings. When this difference between the treatment arms was
abolished the clinical benefit with faster aspart fell to 0.05 QALYs. The
analyses with alternative HbA1c progression approaches reflect the
uncertainty around long-term changes in HbA1c and that patients with
T1DM may develop some characteristics of T2DM, with faster aspart
remaining associated with improved outcomes and reduced costs com-
pared with insulin aspart in all analyses conducted.
Using the static approach to disutilities applied after non-severe
hypoglycaemic events resulted in reduced quality-adjusted life
expectancy in both arms relative to the base case, with the benefit
associated with faster aspart falling to 0.12 QALYs. Similarly, when
no hypoglycaemia disutilities were applied, the quality-adjusted life
expectancy benefit with faster aspart was 0.12 QALYs. Probabilistic
sensitivity analysis showed similar mean results to those of the base
case, but increased measures of variance around the mean out-
comes. Assuming a willingness-to-pay threshold of £20 000 per
QALY gained, the analysis indicated that there was an 87.0% proba-
bility that faster aspart would be cost-effective vs insulin aspart.
4 | DISCUSSION
Based on clinical effectiveness data from the onset 1 trial, the pres-
ent analysis projected that basal-bolus insulin therapy with faster
aspart plus insulin detemir was likely to improve clinical outcomes
vs basal-bolus insulin therapy with insulin aspart plus insulin detemir
for patients with T1DM in the UK setting. The key driver of
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improved clinical outcomes was a greater improvement in HbA1c,
resulting in a reduced incidence and increased time to onset of
diabetes-related complications. This led to improvements in both dura-
tion and quality of life in the faster aspart arm. The improvements in
glycaemic control associated with faster aspart in onset 1 were
achieved with a similar risk of hypoglycaemic events to that associated
with insulin aspart treatment, as opposed to previous observations
where improvements in glycaemic control have been compromised by
an association with an increase in hypoglycaemic events.5,6 Projected
over patient lifetimes, faster aspart was associated with cost savings as
a result of diabetes-related complications avoided, which were appar-
ent from the first year of the analysis and increased over time. Faster
aspart was also associated with cost savings resulting from lower doses
of both basal and bolus insulins, as the two formulations are associated
with the same acquisition cost. Faster aspart was considered cost- and
life-saving vs insulin aspart as part of a basal-bolus insulin regimen for
treatment of T1DM in the UK setting.
While the improvement in HbA1c with faster aspart compared
with insulin aspart may be relatively modest (0.15%), maintaining this
difference over the long term may substantially reduce the risk of
developing diabetes-related complications. This reduces both mortal-
ity and morbidity associated with T1DM. For healthcare payers, this
improved patient management may also result in significant cost sav-
ings as a result of avoidance of costly treatment of complications.
The present modelling analysis does not take into account
changes in PPG control, as this variable cannot be captured in the
QuintilesIMS CORE Diabetes Model. In the onset 1 study, faster
aspart was associated with statistically significant improvements in
PPG increments compared with insulin aspart.10 It has been sug-
gested that lower PPG may be associated with a reduced risk of
diabetes-related complications, with guidance from the International
Diabetes Federation stating that post-meal hyperglycaemia is inde-
pendently associated with macrovascular disease, ophthalmic disease
and cancer.41 A 2012 review found that higher PPG was associated
with increased all-cause and cardiovascular mortality, increased inci-
dence of major cardiovascular events, and progression of diabetic ret-
inopathy.42 However, the impact of reduced PPG may to some
extent be indirectly included in the present analysis, as HbA1c was
used as the measure of glycaemic control. Some studies have
TABLE 3 Results of the sensitivity analyses
Analysis
Discounted quality-adjusted
life expectancy, QALYs Discounted direct costs, £
ICER
Faster
aspart
Insulin
aspart Difference
Faster
aspart
Insulin
aspart Difference £ per QALY gained
Base case 11.54 11.40 +0.13 50 004 51 719 −1715 Faster aspart dominant
30-year time horizon 10.60 10.50 +0.10 41 423 42 974 −1551 Faster aspart dominant
20-year time horizon 8.85 8.79 +0.06 30 468 31 606 −1138 Faster aspart dominant
10-year time horizon 5.55 5.53 +0.02 15 506 15 971 −464 Faster aspart dominant
0% discount rates 19.72 19.40 +0.32 101 998 105 422 −3424 Faster aspart dominant
6% discount rates 8.59 8.51 +0.08 33 511 34 645 −1134 Faster aspart dominant
HbA1c difference abolished 11.45 11.40 +0.05 51 150 51 719 −570 Faster aspart dominant
Blood pressure difference abolished 11.54 11.40 +0.13 50 027 51 719 −1693 Faster aspart dominant
Lipid difference abolished 11.51 11.40 +0.11 49 967 51 719 −1753 Faster aspart dominant
Body mass index difference abolished 11.53 11.40 +0.13 50 023 51 719 −1696 Faster aspart dominant
Hypoglycaemia difference abolished 11.49 11.40 +0.09 50 015 51 719 −1704 Faster aspart dominant
Statistically significant differences only 11.50 11.40 +0.10 50 165 51 719 −1554 Faster aspart dominant
HbA1c benefit abolished after 1 year 11.45 11.40 +0.05 51 061 51 719 −658 Faster aspart dominant
HbA1c benefit abolished after 5 years 11.46 11.40 +0.06 50 564 51 719 −1155 Faster aspart dominant
HbA1c benefit abolished after 10 years 11.49 11.40 +0.09 50 453 51 719 −1267 Faster aspart dominant
HbA1c benefit abolished linearly over 10 years 11.48 11.40 +0.07 50 973 51 719 −746 Faster aspart dominant
HbA1c increasing over time in both arms 11.22 11.07 +0.14 54 121 56 003 −1882 Faster aspart dominant
Cost of complications +20% 11.54 11.40 +0.13 56 847 58 813 −1966 Faster aspart dominant
Cost of complications −20% 11.54 11.40 +0.13 42 713 44 183 −1470 Faster aspart dominant
Static hypoglycaemia disutility 7.95 7.83 +0.12 50 004 51 719 −1715 Faster aspart dominant
No hypoglycaemia disutility 12.80 12.68 +0.12 50 004 51 719 −1715 Faster aspart dominant
Pittsburgh cardiovascular risk equations 10.79 10.69 +0.10 48 130 49 755 −1625 Faster aspart dominant
Combined mortality based on
Western Australia data
12.12 12.00 +0.11 60 104 62 511 −2406 Faster aspart dominant
52-week data 11.47 11.35 +0.12 51 760 53 676 −1916 Faster aspart dominant
25 and 52-week data 11.51 11.37 +0.14 51 483 53 256 −1773 Faster aspart dominant
Probabilistic sensitivity analysis 11.12 11.00 +0.13 49 692 51 448 −1756 Faster aspart dominant
Abbreviations: HbA1c, glycated haemoglobin; ICER, incremental cost-effectiveness ratio.
Costs are in 2015 pounds sterling (£).
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suggested that PPG makes a significant contribution to HbA1c in
patients who are relatively well controlled, although other studies
have been more cautious and have suggested that fasting plasma glu-
cose is a better indicator of HbA1c, particularly in patients with a
very high HbA1c concentration.43,44
In addition to improving glycaemic control, the rapid onset of
action of faster aspart and the faster appearance in the bloodstream
may provide patients with T1DM with increased flexibility around
timing of doses.8,9 Currently, mealtime insulins must be injected pre-
prandially, and this may result in hypoglycaemia if the meal is delayed
or not consumed. Faster aspart represents a mealtime insulin with
the option of post-meal dosing when needed, without compromising
glycaemic control compared with insulin aspart.10 This opportunity
for post-meal dosing, when required, may improve convenience, and
furthermore, flexibility in the timing of insulin dosing has been shown
to be associated with improved quality of life in patients with diabe-
tes, beyond the impact on hypoglycaemic events.45,46 The present
analysis did not capture the utility of flexible insulin dosing, as data
were used from the arms of the trial in which mealtime dosing was
specified, but this impact on quality of life may be seen in real-world
clinical practice, and remains an area of interest for future research.
A limitation of the present analysis, common to a number of
health economic analyses and particularly those for diabetes inter-
ventions, was the reliance on relatively short-term clinical trial data to
make long-term projections. However, in the absence of long-term
trial data, modelled projections represent a valuable source of infor-
mation for healthcare decision-makers aiming to allocate resources
efficiently to maximize healthcare across the population. Further-
more, projecting outcomes over patient lifetimes is recommended in
guidelines for economic evaluation of interventions for patients with
diabetes. The present analysis aimed to minimize the impact of this
by using a model of diabetes based on published long-term epidemio-
logical studies that has been extensively published and validated.13,14
A further limitation may be the clinical data used to inform the
analysis. The study was based on a randomized controlled trial
(onset 1), and therefore there is an assumption that the effects
observed in the trial would be transferable to clinical practice in the
UK setting. Registry data provide evidence of the impact of inter-
ventions in the real world, but it was not possible to use registry
data in the present analysis, as, at the time the analysis was con-
ducted, faster aspart was not available in the UK. As faster aspart
becomes more widely used, data from registries such as the Clinical
Practice Research Datalink could be used to conduct equivalent
long-term analyses. Additionally, data from registries would allow
the clinical effects to be assessed in a larger patient cohort and over
a longer duration than was possible in the onset 1 trial. Neverthe-
less, the onset 1 trial represents the best data source currently
available to inform the present analysis.
Faster aspart has been shown to have a greater glucose-lowering
effect within the first 30 minutes after injection compared with insu-
lin aspart because of its faster appearance within the bloodstream,
and the onset 1 trial found that this resulted in improved glycaemic
control in patients with T1DM. Long-term projections, as part of the
present analysis, suggested that treatment with faster aspart plus
insulin detemir was likely to improve long-term clinical outcomes for
patients with T1DM at a reduced cost from a UK healthcare payer
perspective vs insulin aspart plus insulin detemir.
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